Glumetinib Approval in China: A Major Breakthrough for MET-Positive Lung Cancer
On March 8, 2023, China’s National Medical Products Administration (NMPA) announced a significant glumetinib approval—the conditional…
News
New Hope for Advanced Nasopharyngeal Carcinoma: Becotatug Vedotin Receives Regulatory Approval
Hong Kong DengYue Medicine News – October 30, 2025 – Lepu Biopharma Co., Ltd. (“Lepu Bio”)…
From a Regional Mystery to a Global Breakthrough: The Scientific Journey of Nasopharyngeal Carcinoma Treatment
Nasopharyngeal carcinoma (NPC) was once regarded as a mysterious regional disease, as its incidence was…
Telitacicept Mechanism of Action—A Chinese Innovative “Dual-Target” Breakout
In the field of autoimmune disease treatment, 2021 marked a significant milestone—the world’s first-in-class dual-target…
The IgA Nephropathy New Treatment Revolution: From Supportive Care to Precision Targeting
IgA nephropathy is the most common primary glomerular disease in China, accounting for approximately 40%–50%…
A Breakthrough in Fatal Pulmonary Fibrosis! World’s First PDE4B Inhibitor—Nerandomilast Approved in China
For approximately 5.6 million patients worldwide living with progressive pulmonary fibrosis (PPF), every breath is…
What Causes Plaque Psoriasis? How Does the New Drug Mufemilast Offer a Novel Treatment Choice?
🤔 When well-defined red patches covered in silvery-white scales appear on the skin, it is…
Landmark Approval: Datopotamab Deruxtecan Approval in China, Signaling a Major Shift in Breast Cancer Treatment Landscape
China’s breast cancer treatment landscape has reached a new milestone with the regulatory approval of…
Combating the “Silent Killer”: How Atrasentan is Redefining Primary IgA Nephropathy Treatment and Altering the Course to Kidney Failure
🤔 In China, what is the most common primary glomerulonephritis leading to kidney failure in…
2025 in Review丨Dual Harvest for China Innovative Drugs — How R&D Leadership Met Capital Validation
The year 2025 marked a profound paradigm shift for China’s innovative drug industry. We witnessed…
Copyright@ 2016-2024 Hong Kong Deng Yue Med Al Rights